PTH和SDF-1联合应用对人牙周膜干细胞增殖、迁移及分化的影响
发布时间:2019-03-31 11:23
【摘要】:目的:基质细胞衍生因子-1(stromal cell derived factor-1,SDF-1)是原位组织工程中最重要的趋化因子之一,对人牙周膜干细胞有趋化和促增殖分化作用,局部应用能够促进牙周组织再生。甲状旁腺激素(parathyroid hormone, PTH)作为唯一得到美国食品和药物管理局(Food and Drug Administration, FDA)批准的用于治疗骨质疏松的骨合成代谢药物,能够动员骨髓基质细胞进入血液,并抑制蛋白二肽基肽酶-Ⅳ(dipeptidyl peptidase-Ⅳ, DPP-Ⅳ)对 SDF-1的降解。目前PTH和SDF-1联合应用促进组织再生的研究更多的是集中心脏损伤方面,应用于牙周组织再生方面的研究甚少。本研究的目的是探讨PTH和SDF-1联合应用对人牙周膜干细胞增殖、迁移及分化的影响,为牙周组织再生的深入研究提供实验依据。方法:从因正畸需要而拔除的健康前磨牙上分离、培养人牙周膜干细胞(human periodontal ligament stem cells, hPDLSCs),用有限稀释法筛选单细胞克隆;通过细胞活力检测试剂盒(cell-counting kit-8, CCK8)、细胞迁移试验、碱性磷酸酶(Alkaline phosphatase, ALP)活性测试、茜素红染色法和实时定量聚合酶链反应(quantitative real-time polymerase chain reaction, qRT-PCR)测定PTH与SDF-1联合应用对hPDLSCs增殖、迁移能力和成骨分化能力的影响。使用SPSS 16.0统计软件进行单因素方差分析,数据均用Mean±SEM表示。P0.05具有统计学差异。结果:①成功分离培养出人牙周膜干细胞,细胞形态正常,状态良好。②PTH与SDF-1联合应用能够促进PDLSCs的增殖和迁移能力:CCK8结果表明PTH与SDF-1联合应用促进细胞增殖的效应最强(P0.05);迁移实验表明实验组均能够促进牙周膜干细胞的迁移(P0.05),联合PTH之后使SDF-1的促迁移效应更强(P0.05)。③PTH与SDF-1联合应用能够促进PDLSCs的成骨分化:ALP活性测试结果是细胞培养7天时PTH与SDF-1联合应用能够显著增加ALP活性(P0.05),细胞培养14天时实验组与对照组之间的ALP活性已无显著性差异(P0.05),表明PTH与SDF-1联合应用在细胞培养的早期能增加ALP活性;茜素红染色结果表明PTH与SDF-1联合应用能够显著促进矿化结节的形成CP0.05);qRT-PCR结果显示PTH与SDF-1联合应用能够上调成骨相关标志物BSP、Runx2、OCN的基因表达水平(P0.05)。结论:本实验证实PTH与SDF-1联合应用能够更大程度的促进人牙周膜干细胞增殖、迁移及成骨分化。
[Abstract]:Objective: stromal cell derived factor-1 (stromal cell derived factor-1,SDF-1) is one of the most important chemokines in situ tissue engineering. Local application can promote periodontal tissue regeneration. Parathyroid hormone (parathyroid hormone, PTH), the only bone synthesis metabolic drug approved by the U.S. Food and Drug Administration (Food and Drug Administration, FDA) for the treatment of osteoporosis, mobilizes bone marrow stromal cells into the blood. The degradation of SDF-1 by protein dipeptidyl peptidase 鈪,
本文编号:2450855
[Abstract]:Objective: stromal cell derived factor-1 (stromal cell derived factor-1,SDF-1) is one of the most important chemokines in situ tissue engineering. Local application can promote periodontal tissue regeneration. Parathyroid hormone (parathyroid hormone, PTH), the only bone synthesis metabolic drug approved by the U.S. Food and Drug Administration (Food and Drug Administration, FDA) for the treatment of osteoporosis, mobilizes bone marrow stromal cells into the blood. The degradation of SDF-1 by protein dipeptidyl peptidase 鈪,
本文编号:2450855
本文链接:https://www.wllwen.com/yixuelunwen/kouq/2450855.html
最近更新
教材专著